WHO Drug Information Vol. 25, No. 2, 2011

WHO Drug Information Vol. 25, No. 2, 2011 Proposed INN: List 105lorediplonumlorediplonlorédiplonlorediplónN-{2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl}-N-methylacetamideanxiolyticN-{2-fluoro-5-[3-(thiophéne-2-carbonyl)pryrazolo[1,5-a]pyrimidin-7-yl]phényl}-N-méthylacétamideanxiolytiqueN-{2-fluoro-5-[3-(tiofeno-2-carbonil)pirazolo[1,5-a]pirimidin-7-il]fenil}-N-metilacetamidaansiolíticoC 20 H 15 FN 4 O 2 S 917393-39-6OCH 3NNNSH 3 CNOFlumacaftorumlumacaftorlumacaftorlumacaftor3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido]-3-methylpyridin-2-yl}benzoic acidCFTR (Cystic fibrosis Transmembrane Regulator) channel activatoracide 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido]-3-methylpyridin-2-yl}benzoïqueactivateur de la protéine régulatrice de la perméabilité (CFTR)transmembrainre impliquée dans la mucoviscidoseácido 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-il)ciclopropano-1-carboxamido]-3-metilpiridin-2-il}benzoicoactivateur del canal CFTR (regulador de la conductanciatransmembrana de la fibrosis quística)C 24 H 18 F 2 N 2 O 5 936727-05-8FOHNNCO 2 HFOOCH 3lurbinectedinumlurbinectedin(1'R,6R,6aR,7R,13S,14S,16R)-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-19-oxo-2',3',4',6,7,9',12,13,14,16-decahydro-6aH-spiro[7,13-azano-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-pyrido[3,4-b]indol]-5-yl acetateantineoplastic179